Trademark: 88408993
Status Date
Monday, December 5, 2022
Filing Date
Tuesday, April 30, 2019
Published for Opposition
Tuesday, September 8, 2020
Abandoned Date
Monday, December 5, 2022
5 pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors
42 research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals
Dec 5, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Dec 5, 2022
Abandonment - No Use Statement Filed
Apr 29, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 27, 2022
Sou Extension 3 Granted
Apr 27, 2022
Sou Extension 3 Filed
Apr 27, 2022
Teas Extension Received
Oct 8, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 6, 2021
Sou Extension 2 Granted
Oct 6, 2021
Sou Extension 2 Filed
Oct 6, 2021
Teas Extension Received
Apr 29, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 27, 2021
Sou Extension 1 Granted
Apr 27, 2021
Sou Extension 1 Filed
Apr 27, 2021
Teas Extension Received
Nov 3, 2020
Noa E-Mailed - Sou Required From Applicant
Sep 8, 2020
Official Gazette Publication Confirmation E-Mailed
Sep 8, 2020
Published For Opposition
Aug 19, 2020
Notification Of Notice Of Publication E-Mailed
Aug 3, 2020
Approved For Pub - Principal Register
Jul 24, 2020
Teas/Email Correspondence Entered
Jul 23, 2020
Correspondence Received In Law Office
Jul 23, 2020
Teas Request For Reconsideration Received
Feb 4, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 4, 2020
Teas Change Of Owner Address Received
Jan 25, 2020
Notification Of Final Refusal Emailed
Jan 25, 2020
Final Refusal E-Mailed
Jan 25, 2020
Final Refusal Written
Jan 14, 2020
Teas/Email Correspondence Entered
Jan 14, 2020
Correspondence Received In Law Office
Jan 14, 2020
Teas Response To Office Action Received
Jul 15, 2019
Notification Of Non-Final Action E-Mailed
Jul 15, 2019
Non-Final Action E-Mailed
Jul 15, 2019
Non-Final Action Written
Jul 12, 2019
Assigned To Examiner
May 16, 2019
New Application Office Supplied Data Entered
May 3, 2019
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
